TheJakartaPost

Please Update your browser

Your browser is out of date, and may not be compatible with our website. A list of the most popular web browsers can be found below.
Just click on the icons to get to the download page.

Jakarta Post

Ending HIV, hepatitis by 2030 unlikely without drug-policy reform

World governments need to decriminalize drug use, drug possession for personal use, and the possession of drug paraphernalia.  

Rita A. Widiadana (The Jakarta Post)
Premium
Denpasar, Bali
Fri, December 1, 2023

Share This Article

Change Size

Ending HIV, hepatitis by 2030 unlikely without drug-policy reform Nurses at the HIV integrated care unit of Cipto Mangunkusumo government hospital in Jakarta attend to an HIV patient infected from drug use on Nov. 30, 2012 as Indonesia battles HIV/AIDS. (AFP/Romeo Gacad)

A

em>Ahead of World AIDS Day, which falls on Dec.1, the Global Commission on Drug Policy publishes a report saying that an end to the HIV and hepatitis epidemics will remain elusive without drug policy reform and the participation of people using drugs worldwide. To learn more about the report, Rita Widiadana spoke with Adeeba Kamarulzaman, former president of the International AIDS Society and member of the Geneva-based Global Commission on Drug Policy, for The Jakarta Post. The following are excerpts from the discussion.

Question: How is the current global HIV and hepatitis situation and what is the world’s response to these epidemics?

In 2023, approximately 354 million people around the world are currently living with hepatitis B or C—that is more than the current population of the United States. People who use drugs, especially people who inject drugs, are at a higher risk for blood-borne HIV, hepatitis B (HBV) and hepatitis (HCV).

HIV and HCV infections are major public health threats worldwide. Studies reveal that people who inject drugs are greatly affected by both infections. Nearly one in five people who inject drugs are living with HIV and over a third live with HCV.

Globally, an estimated 14.8 million people inject drugs. In 2022, there will be around 5.8 million people who inject drugs living with HCV and 2.2 million people who inject drugs living with HIV.

In Indonesia, viral hepatitis is a significant public health issue. Currently, around 19 million people are infected with HBV and 2.5 million are infected with HCV, and mortality is increasing from both infections, according to Health Ministry data.

Viewpoint

Every Thursday

Whether you're looking to broaden your horizons or stay informed on the latest developments, "Viewpoint" is the perfect source for anyone seeking to engage with the issues that matter most.

By registering, you agree with The Jakarta Post's

Thank You

for signing up our newsletter!

Please check your email for your newsletter subscription.

View More Newsletter

With an estimated 800,000 people living with HIV in Indonesia, around 29 percent are people who also inject drugs.

to Read Full Story

  • Unlimited access to our web and app content
  • e-Post daily digital newspaper
  • No advertisements, no interruptions
  • Privileged access to our events and programs
  • Subscription to our newsletters
or

Purchase access to this article for

We accept

TJP - Visa
TJP - Mastercard
TJP - GoPay

Redirecting you to payment page

Pay per article

Ending HIV, hepatitis by 2030 unlikely without drug-policy reform

Rp 29,000 / article

1
Create your free account
By proceeding, you consent to the revised Terms of Use, and Privacy Policy.
Already have an account?

2
  • Palmerat Barat No. 142-143
  • Central Jakarta
  • DKI Jakarta
  • Indonesia
  • 10270
  • +6283816779933
2
Total Rp 29,000

Your Opinion Matters

Share your experiences, suggestions, and any issues you've encountered on The Jakarta Post. We're here to listen.

Enter at least 30 characters
0 / 30

Thank You

Thank you for sharing your thoughts. We appreciate your feedback.